DOI:
10.1055/s-00000005
Aktuelle Rheumatologie
LinksClose Window
References
Jamnitski A, Bartelds GM, Nurmohamed MT. et al.
The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept.
Annals of the rheumatic diseases 2011;
70: 284-288
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.